Mylan is focused on closing its merger with Pfizer’s Upjohn next year. But after that deal closes, the pumped-up company should have the firepower for more M&A deals, an exec said. Meanwhile, the company canned 350 products in a cleanout of its current portfolio.
More: Think Mylan's done with M&A after its Pfizer deal? Think again